Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium

• Published in: International journal of methods in psychiatric research 2006-01, Vol.15 (3), p.131-138
• Main Authors: Morgello, S., Holzer III, C.E., Ryan, E., Young, C., Naseer, M., Castellon, S.A., Frol, A.B., Atkinson, J. Hampton, Gelman, B.B., Grant, I., Singer, E.J.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Cannabis; Comorbidity; Depressive Disorder, Major - chemically induced; Depressive Disorder, Major - diagnosis; Diagnosis, Dual (Psychiatry); Female; Health Surveys; HIV; HIV Infections - physiopathology; HIV Infections - psychology; Human immunodeficiency virus; Humans; interrater reliability; Interview, Psychological; Male; Middle Aged; Observer Variation; PRISM; Psychiatry - methods; Substance-Related Disorders - classification; Substance-Related Disorders - diagnosis
• ISSN: 1049-8931; 1557-0657
• DOI: 10.1002/mpr.189

The interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) was assessed in a multicentre study. Four sites of the National NeuroAIDS Tissue Consortium performed blinded reratings of audiotaped PRISM interviews of 63 HIV‐infected patients. Diagnostic modules for substance‐use disorders and major depression were evaluated. Seventy‐six per cent of the patient sample displayed one or more substance‐use disorder diagnoses and 54% had major depression. Kappa coefficients for lifetime histories of substance abuse or dependence (cocaine, opiates, alcohol, cannabis, sedative, stimulant, hallucinogen) and major depression ranged from 0.66 to 1.00. Overall the PRISM was reliable in assessing both past and current disorders except for current cannabis disorders when patients had concomitant cannabinoid prescriptions for medical therapy. The reliability of substance‐induced depression was poor to fair although there was a low prevalence of this diagnosis in our group. We conclude that the PRISM yields reliable diagnoses in a multicentre study of substance‐experienced, HIV‐infected individuals. Copyright © 2006 John Wiley & Sons, Ltd.